Your session is about to expire
← Back to Search
Bendamustine +/- Cyclophosphamide to Prevent GVHD Post Stem Cell Transplant for Blood Cancers
Study Summary
This trial is testing bendamustine, with or without cyclophosphamide, to see if it can help prevent GVHD in patients undergoing stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 77 Patients • NCT01251575Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have no lasting side effects above mild from previous cancer treatments.I am HIV positive.The donor's tissue type is not a close match to yours.I can take care of myself but may not be able to do heavy physical work.My kidney function, measured by creatinine levels, is within the required range.I am unable or unwilling to sign the consent form.I have active hepatitis B or C.I have a blood cancer.I do not have any active or uncontrolled infections.I do not have active liver or bile duct diseases, except for Gilbert's syndrome.I do not have acute leukemia in first remission or chronic myeloid leukemia in its first chronic phase.
- Group 1: Schedule II (lymphoid malignancies)
- Group 2: Schedule I (non-lymphoma)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what medical conditions is Allogeneic Hematopoietic Stem Cell Transplantation most commonly employed?
"Allogeneic Hematopoietic Stem Cell Transplantation is a widely accepted treatment for lung cancer and has been used to assuage the symptoms of dermatitis, atopic, multiple sclerosis, and b-cell lymphomas."
Who qualifies to take part in this medical experiment?
"To be considered, applicants must suffer from neoplasms and range in age between 18-70 years old. This medical study is currently seeking approximately 40 participants."
Are there any other experiments involving Allogeneic Hematopoietic Stem Cell Transplantation that have been conducted previously?
"Currently, 1361 studies related to Allogeneic Hematopoietic Stem Cell Transplantation are in progress. Of these trials, 260 have reach Phase 3 status. The majority of research for this therapy has been conducted at Bethesda, Maryland; however, 40052 sites globally offer the treatment."
Does this trial include elderly individuals in its recruitment efforts?
"According to the criteria listed, only individuals aged between 18-70 are eligible for enrolment. However, there are 392 studies available for minors and 1101 trials catered towards persons over 65 years old."
Is this medical research project accepting participants presently?
"According to the details of this trial hosted on clinicaltrials.gov, enrolment for participants is currently open. The experiment was initially announced on March 13th 2020 and has been modified most recently on September 7th 2022."
What is the upper bound of participants involved in this experiment?
"Affirmative, clinicaltrials.gov attests to this study's ongoing recruitment efforts. The trial kicked off back on March 13th 2020 and was updated most recently on September 7th 2022. 40 participants are required from a single medical centre."
Share this study with friends
Copy Link
Messenger